Browse > Article
http://dx.doi.org/10.4333/KPS.2008.38.5.335

In vitro Dissolution and in vivo Bioequivalence Study of Controlled Release Carbamazepine Formulation (Epileptol CR® vs Tegretol CR® in Healthy Male Korean Volunteers  

Kim, Ji-Young (Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Kim, Hyung-Tae (Hanyang University Medical Center)
Kim, Chong-Kook (Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
Publication Information
Journal of Pharmaceutical Investigation / v.38, no.5, 2008 , pp. 335-342 More about this Journal
Abstract
The bioequivalence of two carbamazepine preparations was conducted. The in vivo bioequivalence study in 20 healthy male Korean volunteers was designed by using a single dose, randomized, 2-period crossover with a 3-weeks washout period between the doses. Prior to the in vivo study, an in vitro comparative dissolution test was performed by the paddle and basket method as described in the bioequivalence guidance of the Korea Food and Drug Administration (KFDA). Based on the similar dissolution pattern between two preparations in the dissolution test, the two formulations are demonstrated to be pharmaceutically equivalent. In addition, in vivo bioequivalence test was used to reconfirm the in vitro dissolution results. In the in vivo bioequivalence study, the plasma concentrations of carbamazepine up to 144 h after the administration were determined using a validated HPLC method with UV detection and the bioequivalence between the two drug products was assessed by statistical analysis of the log transformed mean ratios of $C_{max}$, $AUC_{0-t}$ and $AUC_{0-\infty}$. The mean maximum concentration ($C_{max}$) of the test and reference were found to be $1467.0{\pm}335.8\;ng/mL$ and $1465.9{\pm}310.3\;ng/mL$, respectively. The 90% confidence intervals (C.I.) of $C_{max}$ were in the range from 0.95 to 1.05. As for the $AUC_{0-t}$ and $AUC_{0-\infty}$, test values were $110027.1{\pm}27786.4\;ng/mL{\cdpt}h$, $128807.0{\pm}34563.2\;ng/mL{\cdot}h$ and $105473.6{\pm}26496.2\;ng/mL{\cdot}h$, $125448.5{\pm}35975.5\;ng/mL{\cdot}h$, respectively. The 90% C.I. of $AUC_{0-t}$ were 0.97 to 1.10 and of $AUC_{0-\infty}$, 0.99 to 1.09 and thus were within the log 0.8-log 1.25 interval proposed by the KFDA. A two-way ANOVA showed no significant difference between the two formulations. Based on these statistical analysis, it was concluded that the test formulation is bioequivalent to the reference.
Keywords
Carbamazepine; Bioequivalence; Pharmacokinetics; Dissolution; Controlled release;
Citations & Related Records
연도 인용수 순위
  • Reference
1 A. Verrotti, C. Salladini, G. Di Marco, F. Pisciella and F. Chiarelli, Extended-release formulations in epilepsy, J. Child. Neurol., 22, 419-26 (2007)   DOI
2 E. Spina, Carbamazepine: chemistry, biotransformation, and pharmacokinetics. In: Antiepileptic Drugs. 5th ed. R.H. Levy, R.J. Mattson, B.S. Meldrum and E. Perucca, eds. Baltimore, U.S.A, pp. 236-46 (2002)
3 J. Moreno, A. Belmont, O. Jaimes, J.A. Santos, G. Lopez and M.G. Campos, Pharmacokinetics study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment, Arch. Med. Res., 35, 168-71 (2004)   DOI   ScienceOn
4 M. Bialer, L. Arcavi, S. Sussan, A. Volosov, A. Yacobi and D. Moros, Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine, Epilepsy Res., 32, 371-8 (1998)   DOI   ScienceOn
5 J.K. Pandit, S. Singh and M.S. Muthu, Controlled release formulations in neurology practice, Ann. Indian Acad. Neurol., 9, 207-16 (2006)   DOI
6 S. Dutta, Y. Qiu, E. Samara, G. Cao and G.R. Granneman, Once-a day extended-release dosage form of diavalproex sodium III: Devalopment and validation of a level a in vitro-in vivo correlation (IVIVC), J. Pharm. Sci., 94, 1949-56 (2005)   DOI   ScienceOn
7 S. Hayes, A.Dunne, T. Smart and J. Davis, Interpretation and optimization of the dissolution specifications for a modified release product with an in vitro-in vivo correlation (IVIVC), J. Pharm. Sci., 93, 571-81 (2004)   DOI   ScienceOn
8 Korean Guideline for Bioequivalence Test. Korea Food and Drug Administration, (2005)
9 KW. Sommerville. Bioequivalence in development of antiepileptic drugs, Epilepsy Res., 68, 82-4 (2006)   DOI   ScienceOn
10 M. Bialer, Extended-release formulations for the treatment of epilepsy CNS, Drugs, 21, 765-74 (2007)
11 J.J.I. Tamimi, I.I Salem, S.M. Alam, Q. Zaman and R. Dham, Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers, Biopharm. Drug Dispos., 26, 335-9 (2005)   DOI   ScienceOn
12 F. Bugamelli, C. Sabbioni, R. Mandrioli, E. Kenndler, F. Albani and M.A. Raggi, Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatography after solid-phase extraction, Anal. Chim. Acta., 472, 1-10 (2002)   DOI   ScienceOn
13 Prescribing information $^{Pr}Tegretol$. Novartis Pharmaceuticals Canada Inc., (2006)
14 A. Marzo, L. Dal Bo, A. Rusca and P. Zini, Bioequivalence of ticlopidine hydrochloride administered in single dose to healthy volunteers, Pharmacol. Res., 46, 401-7 (2002)   DOI   ScienceOn
15 R. Mandrioli, F. Albani, G. Casamenti, C. Sabbioni and M.A. Raggi, Simultaneous high-performance liquid chromatography determination of carbamazepine and five of its metabolites in plasma of epileptic patients, J. Chromatogr. B, 762, 109-16 (2001)   DOI   ScienceOn
16 J.A. Cramer, R.H. Mattson, M.L. Prevey and R.D. Scheyer, Ouellette, V.L. How often is medication taken as prescribed? A novel assessment technique, JAMA, 261, 3273-7 (1989)   DOI
17 P. Pienimaki, S. Fuchs, J. Isojarvi and K. Vahakangas, Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high-performance liquid chromatography, J. Chromatogr. B, 673, 97-105 (1995)   DOI   ScienceOn